Sign In
Get Clay Free →

Suggestions

    Ricardo Dolmetsch

    President Tempero Bio

    Ricardo Dolmetsch is a prominent figure in the biotechnology industry, notably recognized for his contributions to the development of gene therapies for life-threatening diseases. With a rich academic background and extensive professional experience, Dolmetsch has held key positions in various prestigious organizations, showcasing his expertise in neuroscience and research.

    Dolmetsch served as the President and Chief Scientific Officer at uniQure, a leading company focused on gene therapies targeting severe liver and nervous system conditions. During his tenure, he played a pivotal role in spearheading the development of innovative gene therapy treatments like Hemgenix for Hemophilia B and AMT-130 for Huntington’s disease, establishing himself as a trailblazer in the field.

    Prior to his time at uniQure, Dolmetsch held the position of Global Head of Neuroscience at Novartis, where he was instrumental in establishing and leading the research and early development team. His contributions at Novartis led to significant advancements in treatments for conditions such as migraine and multiple sclerosis, with the development of groundbreaking medications like Aimovig, Mayzent, and Kesimpta.

    In addition to his corporate roles, Dolmetsch has a strong academic background, having served as a Professor at Stanford Medical School and as a faculty member at Stanford University Bio-X. His educational journey includes a Ph.D. in Neuroscience from Stanford University, complemented by a B.Sc. in Neuroscience from Brown University. Dolmetsch's postdoctoral training at Harvard Medical School and Boston Children’s Hospital further enriched his understanding of neurological and psychiatric diseases.

    Furthermore, Dolmetsch's research contributions have been pioneering, particularly in the utilization of induced pluripotent stem cells to model complex neurological and psychiatric disorders. His work has significantly contributed to advancing knowledge on the role of calcium channels in the development and function of the nervous and immune systems.

    Currently serving as the founder and President of Tempero Bio, Dolmetsch continues to drive innovation in the biotechnology sector, focusing on developing treatments for substance use disorders. His diverse skill set, encompassing both academic and corporate expertise, positions him as a notable authority in the field of neuroscience and gene therapy.

    Ricardo Dolmetsch
    Add to my network

    Location

    Concord, Massachusetts, United States